Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Shareholders elected three Class III directors — Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr. — to serve until the 2029 Annual Meeting.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. There were 61,853,254 shares of voting common stock entitled to vote as of the April 15, 2026 record date.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 61,853,254 shares
Votes for Mark C. McKenna: 53,689,547 votes
Votes for Jennifer Fox: 52,895,552 votes
+3 more
6 metrics
Shares entitled to vote
61,853,254 shares
Voting common stock as of April 15, 2026 record date
Votes for Mark C. McKenna
53,689,547 votes
Election as Class III director at 2026 Annual Meeting
Votes for Jennifer Fox
52,895,552 votes
Election as Class III director at 2026 Annual Meeting
Votes for William (BJ) Jones, Jr.
44,964,804 votes
Election as Class III director at 2026 Annual Meeting
Auditor ratification votes for
56,960,778 votes
Ratification of Ernst & Young LLP for 2026
Say-on-pay votes for
54,324,725 votes
Advisory approval of named executive officer compensation
Key Terms
Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, non-binding, advisory basis, +1 more
5 terms
Annual Meeting of Stockholders regulatory
"On June 9, 2026, Apogee Therapeutics, Inc. ... held its 2026 Annual Meeting of Stockholders"
broker non-votes financial
"William (BJ) Jones, Jr. ... 10,240,447 ... 1,795,532 broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding, advisory basis regulatory
"The compensation of our named executive officers ... was approved on a non-binding, advisory basis"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
Who was elected to Apogee Therapeutics (APGE) board at the 2026 meeting?
Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr. were elected as Class III directors to serve until the 2029 Annual Meeting. Each nominee received more votes “for” than “withheld,” with McKenna receiving 53,689,547 votes for and Fox 52,895,552 votes for.
What were the voting results on Apogee Therapeutics (APGE) executive compensation?
The compensation of Apogee Therapeutics’ named executive officers, as disclosed in the proxy statement, was approved on a non-binding advisory basis. There were 54,324,725 votes for, 633,959 votes against, 246,567 abstentions, and 1,795,532 broker non-votes, showing majority shareholder support for the pay program.